PPT-Peginterferon alfa-2a versus

Author : morgan | Published Date : 2022-07-15

Interferon alfa2a Phase 3 Treatment Naïve Chronic HCV Zeuzem S et al N Engl J Med 2000343166672 Source Zeuzem S et al N Engl J Med 2000343166672 Peginterferon

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Peginterferon alfa-2a versus" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Peginterferon alfa-2a versus: Transcript

Interferon alfa2a Phase 3 Treatment Naïve Chronic HCV Zeuzem S et al N Engl J Med 2000343166672 Source Zeuzem S et al N Engl J Med 2000343166672 Peginterferon alfa2a versus Interferon alfa. RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . alfa-2a . versus. . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Phase 3. Treatment. . Naïve, Chronic HCV. McHutchison. . JG, et al. N . Engl. J Med. 1998;339:1485-92.. I. nterferon . alfa-. 2b . +/- Ribavirin for Chronic HCV. Study . Outline. Study. -. . Randomized, double-blinded, placebo controlled, phase 3 trial. Overview. . of. . PECS . projects. European Space . Agency Information . Day. 1. 1. th. January. , 2017. Point of Contact: . Ms. . Maite. Trujillo: maite.trujillo@esa.int. Mr. Laurent . Marchand. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . alfa. -. 2b. . + RBV vs. . Peginterferon alfa-. 2a. . + RBV. IDEAL . STUDY. Phase 3, Treatment Naïve. Treatment. . Naïve, Chronic HCV. McHutchison. JG, et. al. N . Engl. J Med. 2009;361:580-93. . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . Editorial April 2018 Alfa Laval reserves the right to change specifications without prior notification. Smooth - running ballast water treatment with Alfa Laval PureBallast 3 Dowa Line, USA, Case s Como ser un Hombre Alfa PDF GRATIS - DESCARGAR LIBRO de Hombres Peligrosos™ » Los secretos para seducir que los chicos alfa no quieren que sepas versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin. ID . : . DB00008 . Protein average . weight : . 60000.0000. . Half life : . Terminal half life is 80 hours (range 50 to 140 hours). . . Description. :. . Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched .

Download Document

Here is the link to download the presentation.
"Peginterferon alfa-2a versus"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.